HACKENSACK, N.J.--(BUSINESS WIRE)--ReGen Biologics (OTC: RGBI) announced today that it has completed a $2.5 million private placement of convertible notes and it has submitted a new 510(k) seeking FDA clearance of its collagen scaffold device for reinforcement and repair of meniscus tissue.
